ClinicalTrials.gg
CompletedNCT03322137Updated Feb 8, 2019

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

A Phase 2 interventional study of SNA-120 and Vehicle in Pruritus and Psoriasis Vulgaris, sponsored by Sienna Biopharmaceuticals. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Sienna Biopharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
42nd of 153
208 · median 70
Started
2017
with 10 others
Phase 2
60 of 163
6 open now
Registered
66th of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 42nd largest by enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2017, is one of 60 in phase 2, and was the 66th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.

03

Conditions studied

  • Pruritus
  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • /assent and Health Insurance Portability and Accountability Act (HIPAA) authorization
  • Stable PV for at least 6 months prior to screening
  • Chronic pruritus of the PV plaques to be present for at least 6 weeks prior to screening
  • Mild to moderate PV at screening and baseline
  • Has a target plaque at baseline on the trunk and/or limbs
  • Subject's plaques are amenable to treatment with a topical ointment medication
  • Willing and able to comply with the study instructions and attend all scheduled study visits.
  • Willing to avoid prolonged exposure of the designated treatment plaques to ultraviolet radiation
  • Females of must have a negative pregnancy test at baseline before randomization and must agree to use highly effective during the study
  • Men who are sexually active and can father children must agree to use highly effective forms of contraception during the study

Exclusion criteria

Exclusion Criteria:

  • Underlying conditions other than psoriasis that, in the opinion of the investigator, currently cause or influence pruritus of the overall skin
  • Positive hepatitis serology
  • Thyroid abnormalities that may impact itching
  • Subjects with spontaneously improving or rapidly deteriorating PV and/or pruritus
  • Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
  • Active psoriasis or itch affecting the palmar/plantar regions
  • Subjects with a clinical diagnosis of bacterial infection of the skin
  • Any major medical illness or symptoms of a illness that may influence the study outcome
  • Any acute chronic medical or psychiatric condition or laboratory abnormality that would make them unsuitable for participation in this study
  • Known to the study treatment and /or polyethylene glycol, that contraindicates participation
  • Currently enrolled in an drug or device study or has used an investigational drug or an investigational device treatment within 30 days of randomization/baseline (Note: Subjects who are enrolled in a long-term follow-up study and are not actively receiving an investigational drug or investigational device treatment may be eligible for participation in this study)
  • Female who is pregnant or lactating, or is planning to become pregnant during the study
  • Subjects participating in any previous SNA-120 (and/or CT327) clinical studies
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Active comparator
    SNA-120 (0.05% )

    Pegcantratinib Ointment

    Drug: SNA-120

  • Active comparator
    SNA-120 (0.5%)

    Pegcantratinib Ointment

    Drug: SNA-120

  • Placebo comparator
    Vehicle

    Drug: Vehicle

Interventions

  • Pegcantratinib ointment

  • DrugVehicle

    Placebo ointment to mimic Pegcantratinib ointment

06

What researchers measure

Primary outcomes

  1. Change in Itch Numeric Rating Scale scores (I-NRS)

    The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

    Time frame: week 1

  2. Change in Itch Numeric Rating Scale scores (I-NRS)

    The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

    Time frame: week 2

  3. Change in Itch Numeric Rating Scale scores (I-NRS)

    The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

    Time frame: week 4

  4. Change in Itch Numeric Rating Scale scores (I-NRS)

    The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

    Time frame: week 6

  5. Change in Itch Numeric Rating Scale scores (I-NRS)

    The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching

    Time frame: week 8

Secondary outcomes

  1. Proportion of subjects (≥ 1 grade change) on IGA scale

    Investigator Global Assessment

    Time frame: week 12

  2. Proportion of subjects (≥ 2 grade change) on IGA scale

    Investigator Global Assessment

    Time frame: week 12

  3. Proportion of subjects categorized as a "0" or "1" on IGA scale and minimum improvement of 2 categories

    Investigator Global Assessment

    Time frame: baseline and week 12

  4. Change in PASI-50

    Percentage of subjects with 50% reductions in Psoriasis Area and Severity Index

    Time frame: baseline and week 12

Other outcomes

  1. Safety measured by incidence and severity of adverse events

    Time frame: up to 12 weeks

  2. Safety measured by change in clinical laboratory results from baseline

    urinalysis lab assessments

    Time frame: up to 12 weeks

  3. Safety measured by change in clinical laboratory results from baseline

    biochemistry lab assessments

    Time frame: up to 12 weeks

  4. Safety measured by change in clinical laboratory results from baseline

    hematology lab assessments

    Time frame: up to 12 weeks

  5. Safety measured by change in blood pressure from baseline

    systolic/diastolic blood pressure (BP in mmHg)

    Time frame: up to 12 weeks

  6. Safety measured by change in pulse from baseline

    Pulse (beats per minute \[bpm\])

    Time frame: up to 12 weeks

  7. Safety measured by number of abnormal physical examination changes

    Any abnormal physical examination changes from baseline and week 12

    Time frame: baseline and week 12

  8. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Time frame: week 2

  9. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Time frame: week 8

  10. Safety measured by PR/PQ intervals measured by 12-lead ECG

    Time frame: week 12

  11. Safety measured by QRS duration measured by 12-lead ECG

    Time frame: week 2

  12. Safety measured by QRS duration measured by 12-lead ECG

    Time frame: week 8

  13. Safety measured by QRS duration measured by 12-lead ECG

    Time frame: week 12

  14. Safety measured by QT interval measure by 12-lead ECG

    Time frame: week 2

  15. Safety measured by QT interval measure by 12-lead ECG

    Time frame: week 8

  16. Safety measured by QT interval measure by 12-lead ECG

    Time frame: week 12

07

Study locations

38 sites
  • Site 025
    Scottsdale, Arizona 85255, United States
  • Sienna 022
    Fort Smith, Arkansas 72916, United States
  • Site 028
    Fountain Valley, California 92708, United States
  • Sienna 009
    Fremont, California 94538, United States
  • Sienna 008
    San Diego, California 92123, United States
  • Sienna 020
    Santa Monica, California 90404, United States
  • Sienna 015
    Denver, Colorado 80220, United States
  • Sienna 005
    Farmington, Connecticut 06032, United States
  • Site 030
    Shelton, Connecticut 06484, United States
  • Site 026
    Doral, Florida 33122, United States
  • Sienna 019
    Largo, Florida 33770, United States
  • Sienna 017
    North Miami Beach, Florida 33162, United States
  • Sienna 024
    Ocala, Florida 34471, United States
  • Site 027
    West Palm Beach, Florida 33406, United States
  • Site 029
    Macon, Georgia 31217, United States
  • Sienna 010
    New Albany, Indiana 47150, United States
  • Sienna 011
    Plainfield, Indiana 46168, United States
  • Sienna 023
    Louisville, Kentucky 40202, United States
  • Site 038
    Metairie, Louisiana 70006, United States
  • Site 032
    Rockville, Maryland 20850, United States
  • Site 039
    Clarkston, Michigan 48346, United States
  • Sienna 002
    Fridley, Minnesota 55432, United States
  • Sienna 001
    Saint Louis, Missouri 63117, United States
  • Sienna 004
    East Windsor, New Jersey 08520, United States
  • Sienna 013
    Albuquerque, New Mexico 87106, United States
  • Site 037
    Rochester, New York 14623, United States
  • Sienna 016
    High Point, North Carolina 27626, United States
  • Sienna 006
    Winston-Salem, North Carolina 27104, United States
  • Site 041
    Norman, Oklahoma 73071, United States
  • Sienna 003
    Portland, Oregon 97223, United States
  • Site 031
    Pittsburgh, Pennsylvania 15213, United States
  • Site 035
    Murfreesboro, Tennessee 37130, United States
  • Sienna 012
    Austin, Texas 78759, United States
  • Sienna 021
    Dallas, Texas 75246, United States
  • Sienna 018
    Houston, Texas 77030, United States
  • Site 034
    Pflugerville, Texas 78660, United States
  • Sienna 007
    Murray, Utah 84107, United States
  • Sienna 014
    Norfolk, Virginia 23502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Sep 2018, 11 months.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 26, 2017
StartActual
Oct 10, 2017
Primary completionActual
Sep 10, 2018
CompletionActual
Oct 22, 2018
Results delay requested
Feb 4, 2019
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03322137
Lead sponsor
Sienna Biopharmaceuticals
Responsible party
Sponsor
First posted
Oct 26, 2017
Start date
Oct 10, 2017
Primary completion
Sep 10, 2018
Completion
Oct 22, 2018
Last update
Feb 8, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcantratinib

Start the discussion